India’s primary market is set for another busy week with five IPOs opening for subscription, including four mainboard issues and one SME listing. However, grey market signals suggest that investor enthusiasm remains muted, with most upcoming offerings showing little to no grey market premium (GMP) so far. The cautious sentiment comes after a weak run for recent IPO listings and broader volatility in equity markets.
Source link
BioMarin sNDA seeking full Voxzogo approval accepted by FDA
An sNDA filed by BioMarin Pharmaceutical (BMRN) seeking full approval of its achondroplasia treatment Voxzogo (vosoritide) has been accepted by...











